


iPSC screening services

The availability of physiologically relevant cell models can make or break a drug discovery campaign as predictive results from cell-based assays are key criteria for progressing candidate molecules. In the past, primary cells were often the only option to achieve this and cost as well as availability were limiting. The reprogramming of somatic cells to induced Pluripotent Stem Cells (iPSCs) has opened novel opportunities to derive diverse cell types in a reproducible and scalable manner.

Assay.Works provides an integrated iPSC platform

- › Cultivation and expansion of iPSC cell lines
- › QC via Immune Fluorescence, FACS, germ layer differentiation, karyotyping*, and STR analysis*
- › Differentiation into specific lineages and cell types
- › Development and optimization of reprogramming and differentiation protocols
- › *De novo* assay development with cell type of your choice
- › Screen development, miniaturization, standardization, protocol automation



Expression of pluripotency marker like Sox2, Nanog, and Oct 3/4 is assessed via IF staining or FACS analysis to maintain a high quality of iPSC culture

End-to-end services from cell model to assay development, and screening

- › A team of seasoned specialists in Lead Discovery across indications, specializing on predictive, functional assays for challenging targets.
- › State of the art infrastructure to run high content screening assays including Cell Painting and AI assisted data analysis.
- › Multiplexing of markers enables efficient generation of meaningful data sets.
- › Option to combine IF staining with RNA FISH probes for markers not accessible with antibodies.
- › Other assay formats include FACS, luminescence, FLIPR, RNAseq* or qPCR*.

* provided by partners

Contact

Assay.Works GmbH
Am BioPark 11
93053 Regensburg, Germany

contact@assay.works | www.assay.works